Chief Science Officer, Global CMC Solutions
David Hedden joined BioDuro’s GCS division, formerly known as Formex, as the the Principal Scientist of Formulation in 2017. He was promoted to Chief Scientific Officer in 2019. He has worked as a Formulation and Process Development scientist with excursions into Material Science, Manufacturing, Regulatory Sciences and Management for large (e.g., Pfizer, DuPont), medium sized (Ironwood, deCODE genetics), and small virtual development companies. Prior to joining BioDuro, he spent the last 7 years with Drug Product CDMOs, 5 years at UPM Pharmaceuticals before joining BioDuro in 2017. He was a Postdoctoral Fellow in the Chemistry Department of Northwestern University and received his PhD in Chemistry from Tulane University.
32 Years of industry experience
Co-inventor on 12 granted and 3 pending Formulation, Process and Instrument U.S. Patents
Co-founded Adagio Pharmaceuticals resulting in invention of Apomorphine Sublingual Film; the product was licensed to Cynapsus and then sold to Sunovion Pharmaceutical resulting in a NDA application in September 2018